The shares of Pharmamar were revalued by 20.82% in the bag during noon after the company made a study that ensured its one of its drugs is effective to combat COVID-19 and its variants.
At the end of January of last year, something similar has occurred with the same antiviral, plitidepsin, whose effectiveness was recognized on that occasion by Science magazine.
In this case, the Life Science Alliance magazine was responsible for publishing an article on Plitidepsin, which has shown “having a powerful antiviral activity in all variants at very low concentrations (nanomolar) with a positive in vitro therapeutic index,” according to collection
Europe press.
The study was directed by Dr. Adolfo García-Sastre, professor at the Microbiology Department of the Icahn School of Medicine Del Mount Sinai, in New York, United States.
García-Sastre said the drug “has powerful antiviral activity not only for SARS-COV-2 and its variants, including delta and omicron, but also against other coronavirus”.
Likewise, the article reviews the data of a clinical trial in which the safety of plitidepsin was demonstrated in patients with the disease that require hospital income.
The essay details the publication, “reached the primary safety objective and showed clinical efficiency.”
It is also highlighted that the study “gathers evidence consistent of an impact mediated by plitidepsin in the viral load, in the inflammatory pathways and in the normalization of lymphopenia,” explains Pharmamar.
The pharmaceutical reached 65.68 euros per share after closing the day from Monday to 54.30 euros.
Throughout 2021, the price of its actions ranged at different times and came over 100 euros.
The evolution of the pandemic and the effectiveness of its drugs have raised and lowering the value of the signature on the stock market.
